Medical/Pharmaceuticals
The Danish National Genome Center Partners with Lifebit to Deliver Nationwide Personalised Medicine
The Danish National Genome Center has awarded Lifebit a four-year contract to implement Lifebit's Federated Trusted Research Environment software, Lifebit CloudOS, withinDenmark's national supercomputing center. LONDON, April 28, 2022 /PRNewswire/ -- Lifebit, whose leading technology enable...
2022-04-28 14:00
2350
WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability
- WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goals (SDGs), as well as with its stakeholders' interests in sustainable business performance. - One example of WuXi Biologics' contribution to society is its rapid, robust pandemic response -- enab...
2022-04-28 08:30
1590
ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting
SUZHOU, China, and ROCKVILLE, MD, April 27, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that updated results from seven studies involving...
2022-04-28 08:18
1385
HealthBeats Raises US$3m Seed Funding Led By Heritas Capital And SEEDS Capital To Expand Remote Vitals Monitoring In Australia And Singapore
SINGAPORE and SYDNEY and NEW YORK, April 28, 2022 /PRNewswire/ -- HealthBeatsTM , aSingapore-based healthtech start-up with end-to-end remote vitals monitoring solution, today announced the close of aUS$3m Seed round led by healthcare investor Heritas Capital together with SEEDS Capital, the inves...
2022-04-28 08:15
2145
CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022
* Results from GEMSTONE-201 study of sugemalimab, the first successful registrational clinical study to date evaluating an anti-PD-(L)1 antibody targeting patients with relapsed or refractory extranodal natural killer/T-cell lymphoma, will be presented in an oral abstract session * The protoc...
2022-04-28 08:00
2141
Zimmer Biomet's mymobility is recognized as "The Care Management Initiative of the Year" by the 2022 Healthcare Asia Medtech Awards
SINGAPORE, April 28, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that the company's mymobility® digital care management platform won "The Care Management Initiative of the Year" award at this year's Healthcare Asia Med...
2022-04-28 08:00
2780
Glooko Appoints Alfonso "Chito" Zulueta, former Eli Lilly & Company Senior Executive, to Board of Directors
PALO ALTO, Calif., April 28, 2022 /PRNewswire/ -- Glooko, Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the appointment of Alfonso "Chito" Zulueta to its Board of Directors. Respected as a leader w...
2022-04-28 07:00
1959
3M Petrifilm Plate Reader Advanced wins gold at 2022 Edison Awards
ST. PAUL, Minn., April 27, 2022 /PRNewswire/ -- 3M Food Safety was named a 2022 Edison Awards™ gold winner in the Commercial Technology category for its 3M™ Petrifilm™ Plate Reader Advanced. The Edison Awards globally recognize, honor and foster innovations and innovators whose solutions make a p...
2022-04-27 22:10
1865
China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, April 27, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...
2022-04-27 20:30
1358
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
MELBOURNE, Australia, April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the United Kingdom Medicines & Healt...
2022-04-27 19:40
1449
HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials
* This is a first-of-its-kind international study initiated in 2019 by HistoIndex to examine artificial intelligence (AI)-based approaches that may provide a more reliable way to assess the range of injury recorded as "hepatocyte ballooning" as a clinical trial endpoint by expert hepatopatholo...
2022-04-27 17:34
1923
Samsung Biologics Reports First Quarter 2022 Financial Results
* Q1'22 revenue of KRW 511.3 billion increased 96% compared to Q1'21. * Q1'22 operating profit of KRW 176.4 billion increased 137% compared to Q1'21. * Stable business operations and utilization rates across Plants 1, 2, and 3. * Proactive investments into long-term growth, capacity, and su...
2022-04-27 14:42
1588
Zymo Research Makes Strategic Investment in Star Array to Develop an Automated Nucleic Acid Extraction/Superfast PCR Platform for the POCT Market
IRVINE, Calif., April 27, 2022 /PRNewswire/ -- Zymo Research and Star Array today announced Zymo Research's strategic investment to acquire an interest in Star Array, a privately owned, biomedical technology company based inSingapore. The investment allows Zymo Research and Star Array to combine ...
2022-04-27 11:00
2296
RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity
Series B financing led by CBC with participation from Temasek's Pavilion Capital, EDBI and GS Holdings RVAC plans to build R&D center and manufacturing facilities in Singapore and China SINGAPORE, April 26, 2022 /PRNewswire/ -- RVAC Medicines Pte. Ltd. ("RVAC"), an emerging messenger RNA (mRNA)...
2022-04-27 10:00
1622
Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018
* Developed in-house by internal R&D Team at Antengene, ATG-018 is an orally-available, small molecule ATR inhibitor that targets DNA Damage Response (DDR) pathways. * The Phase I study will evaluate the safety, pharmacology and preliminary efficacy of ATG-018 in patients with advanced solid ...
2022-04-27 08:30
1839
VISTA Eye Specialist (VISTA) Opens its 12th Outlet with Massive Success
PETALING JAYA, Malaysia, April 27, 2022 /PRNewswire/ -- VISTA officially opened
inMalaysia's 5th largest city - Ipoh, marking its 12th outlet in the country.
It presently has seven branches in Klang Valley, three inPenang (Northern
Malaysia) and one in Johor Bahru (Southern Malaysia).
2022-04-27 08:00
2653
Taiyo Corporation Introducing OPELAIII "Subscription Style" Rental Purchase Plan
Once subscription ends, the units can be redistributed as used equipment to countries with strong demands and thereby meet SDGs requirement TOKYO, April 27, 2022 /PRNewswire/ -- Taiyo Corporation (Headquarter: Tokyo, Japan / President: Mariko Koizumi), the manufacturer of Wearable Surgical Light...
2022-04-27 06:00
1780
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia
NEW YORK and HONG KONG, April 27, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-400945, a first in...
2022-04-27 04:30
1876
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
AUSTIN, Texas, April 27, 2022 /PRNewswire/ -- Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV ...
2022-04-27 00:09
2297
Seegene unveils world's first commercialized '3 Ct' PCR assay
* Provides Ct value of three targets in one channel; '3 Ct' PCR assay to launch in H1 * "Dream MDx technology" developed based on Seegene's 20-year expertise; combines 19 different patented technologies, including DPO™, TOCE™, MuDT™ * '3 Ct' to lay foundation for automated syndromic testing ...
2022-04-26 20:32
1684
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 276 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 274 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
7117
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
4663
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
2024-04-23 15:43
4532